Epitalon (Epithalon, Epithalamin tetrapeptide)
Synthetic tetrapeptide (Ala-Glu-Asp-Gly), Russian longevity research
At a glance
What it is: Synthetic tetrapeptide (Ala-Glu-Asp-Gly), Russian longevity research.
Primary research applications:
- Claimed: telomerase activation and longevity
- Claimed: sleep and melatonin regulation
Editorial summary: Epitalon has been studied for decades by a single Russian research institute (St. Petersburg Institute of Bioregulation and Gerontology) with reports of longevity and telomerase-activating effects. Independent replication outside this institute is absent, which is a major caveat.
What is Epitalon?
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the Institute of Bioregulation and Gerontology in St. Petersburg as a synthetic analog of peptides said to be extracted from the pineal gland (epithalamin). Nearly all published research originates from this institute and affiliated researchers.[1]
Mechanism of action
Claimed to:
- Stimulate telomerase activity in somatic cells
- Restore pineal/melatonin regulation
- Modulate circadian and hormonal rhythms
Most of these claims rest on work from the originating institute; mechanisms have not been independently confirmed by major international labs.
What the research shows
The peer-reviewed literature on Epitalon is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity, supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Extends human lifespan | Non-replicated regional evidence; no independent RCT confirmation | Preliminary |
| Activates telomerase | Claimed in originating-group studies; independently verified effects are more limited | Uncertain |
| Restores sleep/melatonin patterns | Anecdotal; limited controlled data | Preliminary |
Reported user experiences
How the research describes administration
Subcutaneous injection in grey-market use. Original Russian protocols used short courses (10 consecutive days) twice yearly, but these regimens are not validated by independent trials.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness; these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
⚠ Regulatory update (July 2026): On July 23-24, 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted to recommend Epitalon for the 503A Bulks List, 7-5 with one abstention, against the advice of FDA's own staff reviewers. The vote is advisory: FDA must still complete notice-and-comment rulemaking before compounding eligibility actually changes, realistically into 2027 or later. See our FDA PCAC July 2026 review for the full context.
Epitalon is widely marketed for longevity based on a body of work that has not been independently reproduced at international-journal rigor. The anti-aging claim remains outside the mainstream scientific consensus. If it works as advertised, it would be one of the more remarkable findings in longevity medicine, which is exactly why independent replication matters and is notable for its absence.
Frequently asked questions
Does epitalon actually activate telomerase?
Claims come primarily from the originating Russian research group. Independent confirmation at the level needed to support clinical use is limited.
Is epitalon safe?
Short-term use appears well-tolerated in available reports. Long-term data outside a single research program is limited.
Why is epitalon research mostly Russian?
The compound was developed at a single institute and most downstream studies have been done by affiliated researchers. This concentration is unusual for a compound with the breadth of claimed effects and should inform how confidently we interpret the findings.
Regulatory status (July 2026)
Epitalon was one of seven peptides reviewed by the FDA Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026 for possible addition to the 503A Bulks List, evaluated for insomnia. On July 24 the committee voted to recommend it, 7-5 with one abstention — overriding FDA's own staff reviewers, who had advised against all seven on grounds of insufficient characterization and limited human data.
This does not change what may legally be compounded today. A PCAC vote is advisory: FDA must still act through notice-and-comment rulemaking before any substance joins the 503A list, a process realistically running into 2027 or later, and the agency can decline to follow the recommendation. Epitalon remains not an FDA-approved drug. For the full picture across all seven compounds, see our July 2026 FDA PCAC review.
References
- Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. https://pubmed.ncbi.nlm.nih.gov/14523363/
- Khavinson VK, et al. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2014;156(6):824-8. https://pubmed.ncbi.nlm.nih.gov/24824962/